Jump to content
Powered by

Red biotechnology

The latest articles, press releases and dossiers on red biotechnology in Baden-Württemberg

  • Press release - 27/09/2018

    University takes next hurdle in the German government’s Excellence Strategy funding program. The University of Tübingen is to have three new Clusters of Excellence.As part of the German government’s Excellence Strategy funding forhigher education research, Tübingen will host new outstanding research networks starting in January 2019. Representatives of Germany’s higher education policymakers announced the decision in Bonn on Thursday.

  • Press release - 27/09/2018

    Two Clusters of Excellence for the University of Freiburg: Biological Signalling Studies and Bioinspired Materials Research. It is a major boost to cutting-edge research in Freiburg: in the current Excellence Strategy competition, scientists at the University of Freiburg have been granted two Clusters of Excellence, CIBSS – Centre for Integrative Biological Signalling Studies, and livMatS – Living, Adaptive and Energy-autonomous Materials…

  • Press release - 27/09/2018

    BIOPRO Baden-Württemberg’s new industry report entitled "The Healthcare Industry 2018: Facts and Figures for Baden-Württemberg" has just been published in both German and English. The topic neatly dovetails with the state’s political activities. An evaluation of the region carried out on behalf of the Baden-Württemberg government has clearly recognised the importance of the healthcare sector as a driver of innovation.

  • Article - 06/09/2018

    Microsatellite-unstable cancers are characterised by a large number of mutations within short repetitive DNA sequence regions, and can form novel peptides that the human immune system recognises as neoantigens. These cancers represent a starting point for the development of vaccines to prevent them appearing at an early stage of development. Microsatellite instability is particularly frequent in colon and cervical cancers.

  • Dossier - 28/08/2018

    Diagnosing suitable biomarkers is a prerequisite for tailoring personalised therapies to patient heterogeneity. Genetic tests and genome sequencing play a key role in these diagnoses. Up until now, personalised therapy has achieved the greatest success in the field of oncology. However, personalised treatments are also gaining in importance for treating other diseases. In Baden-Württemberg, the expansion and further development of personalised…

  • Article - 21/08/2018

    Parkinson's disease is one of the most common neurodegenerative diseases in the world. There are around 4.1 million sufferers worldwide. It is characterised by motor impairments that result from the death of certain nerve cells in the brain. Therapies are not yet available. However, researchers at the University of Tübingen have now discovered that vitamin B3 has a positive effect on damaged nerve cells and can boost their energy metabolism.…

  • Press release - 14/08/2018

    The European Research Council (ERC) awards Starting Grants to support excellent young scientists when they are starting an independent science career. In this year's round of proposals, three scientists from the German Cancer Research Center (DKFZ) have been chosen at once for the prestigious award: Ana Banito, Fabian Erdel and Moritz Mall.

  • Article - 14/08/2018

    The junior researchers Dr. Daniel Geiger, Tobias Neckernuß and Jonas Pfeil from Ulm have developed an innovative method for non-contact real-time analysis of cells and other particles. The analysis involves low data rates and correspondingly little effort. This is what makes the method so attractive for medical applications.

  • Article - 08/08/2018

    In late February 2018, Ulm became the tenth German Center for Neurodegenerative Diseases (DZNE) site within the Helmholtz Association. Ulm has long been a world leader in diagnosing and treating rare neurological disorders, notably amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD) and Huntington's disease (HD). We spoke with Professor Albert C. Ludolph, spokesperson for the Ulm DZNE site, medical director of the Clinic for…

  • Article - 31/07/2018

    Deafness is one of the most common sensory disorders in the world: in Germany alone, around eleven million people suffer from hearing loss. So far there is no real therapy, the symptoms can only be alleviated to a greater or lesser degree with hearing aids or assistive devices. This is what researchers from the Tübingen-based company Acousia Therapeutics want to change: they have identified drug candidates that can protect sensory hair cells and…

  • Press release - 20/07/2018

    SHS Gesellschaft für Beteiligungsmanagement has received capital commitments of over €90 million in its fifth fund's first closing. The Tuebingen-based medical technology investor has thus reached almost two thirds of its target of €150 million faster than expected. The fifth generation of SHS funds is also focused on the life sciences and medical technology sector, and thus on the growing global healthcare market with innovative and strong…

Website address: https://www.gesundheitsindustrie-bw.de/en/article/biotech